ONCOC4, INC.

ACTIVE

马里兰州蒙哥马利县, 马里兰州, Australiaoncoc4.comPrivate11–50 employeesEstablished: 2020-01-01

Clinical Trials

5 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2020

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

70.0%

Phase 3

20.0%

Phase 2

10.0%

Trial Status Distribution

Active, not recruiting

40.0%

Completed

10.0%

Enrolling By Invitation

10.0%

Recruiting

30.0%

Withdrawn

10.0%

Clinical Trials

Trials sponsored by this organization (10)

Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors

Phase 1

Recruiting

interventional

Aug 202620 participants

Gotistobart Long Term Extension (LTE) Study

Phase 3

Enrolling By Invitation

interventional

Jul 202620 participants

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

Phase 1

Recruiting

interventional

Mar 2025387 participants

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

Phase 3

Active, not recruiting

interventional

Jun 2023630 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations

ONCOC4, INC.

Overview

Trial Phase Distribution

Trial Status Distribution

Clinical Trials

Trials sponsored by this organization (10)

Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors

Gotistobart Long Term Extension (LTE) Study

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841

ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

Approvals

News